Precision gene therapy company Encoded Therapeutics announced late last month that it has successfully closed its Series C financing round, raising $104 million to be used to develop and bring to market therapeutics aimed at several severe genetic disorders. Specifically, the Bay Area-based biotech startup is planning to use the new capital primarily to fund the development of its marquee program: a precision gene therapy intended to treat Dravet syndrome, a rare form of epilepsy...
Sorry, you need to subscribe to read this article.
If you would like to access this article, please subscribe below.
Premium subscribers receive complete access to our site content which includes market research and insights as well as coverage of the most important news, issues and events related to the healthcare technology industry.